From Pneumococcus to Pseudomonas: the antibacterial behaviour through the time
Abstract
The worldwide use of fluoroquinolones in community and hospital settings, due to their high efficacy and tolerability, to the wide antibacterial spectrum and to the availability of an oral formulation, has created a relevant selective pressure for the emergence of resistant bacterial strains towards this antimicrobial class. Nevertheless, twenty years after development of first fluoroquinolones (e.g. norfloxacin and ciprofloxacin) and ten years after levofloxacin introduction, the antibacterial activity of these drugs remains, on the whole, high.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.